Status
Conditions
Treatments
About
This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Part A - DCD Donor Hearts & DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):
Donor Inclusion Criteria
Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is <50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.
DBD donor hearts with an expected cross clamp of ≥ 4 hours
DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:
Donor Exclusion • Moderate to severe aortic incompetence
Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):
Donor Inclusion Criteria
Donor Exclusion
Moderate to severe aortic incompetence
DBD donor with any of the following organ quality concerns:
Recipient Eligibility Criteria (for Part A and B Cohorts)
Inclusion
Exclusion
• Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial
Primary purpose
Allocation
Interventional model
Masking
655 participants in 3 patient groups
Loading...
Central trial contact
Kausar Qidwai; Raicca Haqqi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal